@article {MaquedaP6.441作者={何塞玛丽亚卡布瑞拉Maqueda Teresa Alba Isasi和卡门·玛丽亚·桑切斯接着说下去! Andres阿罗约特里斯坦弗朗西斯科马丁内斯加西亚和何塞·梅卡Lallana Rocio埃尔南德斯克莱尔},title ={进化为重症肌无力胸腺切除术的临床结果(P6.441)},体积={90}={15}补充数量,elocation-id = {P6.441} ={2018},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:描述临床资料和区分胸腺切除术的临床结果重症肌无力(MG)患者在用作de la Arrixaca Universitary医院。首页背景:胸腺切除术是表示在所有MG胸腺瘤患者无论MG的地位和对病人年龄\ < 60年nonthymomatous,广义乙酰胆碱受体(乙酰胆碱受体)antibody-associated毫克或广义serogenative毫克。设计/方法:回顾性研究2006 {\ textendash} 2016的胸腺切除术是由一个单一的机构的执行。美国使用Myastenia型基金会(MGFA)干预状态分类,完成稳定的缓解,药物缓解和最小Manifestatios和改进被定义为好的临床结果(GCO)和改变,更糟糕的是,恶化或死于MG作为临床疗效不佳(PCO)。结果:46个连续MG胸腺切除术,女性占71.7 \ %(33),平均年龄37岁{\ textpm} 11年。胸腺切除术后1年,13(34岁2 \ %)在PCO组和25 (62、8 \ %)GCO。使用MGFA临床分类,在诊断时没有显著差异(p = 0509)期间或治疗手术后第一年(p = 0.107)。在单变量分析,没有发现显著差异在纵隔成像(或3.929;95 \ % CI, 0.710 21.749 {\ textendash}),手术方法(或1.333;95 \ % CI, 0.194 {\ textendash} 9.186)和乙酰胆碱受体antibody-associated(或2.471;95 \ % CI, 0.250 24.463 {\ textendash})。早期手术干预是PCO病人比GCO组(8 \ % vs 12 \ %;p = 0004)。 Thymomatous myasthenia was associated with poor clinical outcome a year after surgical intervention (OR 4.286; 95\% CI, 0.928{\textendash}19.796). After 10 years of follow-up, 32 (78\%) patients reached a favourable outcome and thymoma was not correlated (OR 1.643; 95\% CI, 0.324{\textendash}8.333).Conclusions: We provide evidence that the benefit of thymectomy is not immediate and it may be related with thymoma presence.Disclosure: Dr. Cabrera Maqueda has nothing to disclose. Dr. Cabrera Maqueda has nothing to disclose. Dr. Garn{\'e}s has nothing to disclose. Dr. Arroyo Tristan has nothing to disclose. Dr. Martinez Garcia has nothing to disclose. Dr. Meca Lallana has nothing to disclose. Dr. Hernandez Clares has nothing to disclose.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/90/15_Supplement/P6.441}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }